Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial

Journal Article · Thu Apr 15 04:00:00 EDT 2021 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2020.12.001· OSTI ID:23200826

Qu, X. Melody ^[1]; Chen, Yujie ^[2]; Zaric, Gregory S. ^[2]; Senan, Suresh ^[3]; Olson, Robert A. ^[4]; others, and

---

1. London Health Sciences Centre, London (Canada)
2. Schulich School of Medicine & Dentistry, Western University, London (Canada)
3. Amsterdam University Medical Center, Vrije Universiteit Medical Center, Amsterdam (Netherlands)
4. British Columbia Cancer, Centre for the North, Prince George (Canada)

The phase 2 randomized study SABR-COMET demonstrated that in patients with controlled primary tumors and 1 to 5 oligometastatic lesions, SABR was associated with improved progression-free survival (PFS) compared with standard of care (SoC), but with higher costs and treatment-related toxicities. The aim of this study was to assess the cost-effectiveness of SABR versus SoC in this setting.

• OSTI ID: 23200826
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 109; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ECONOMIC ANALYSIS
NEOPLASMS
PATIENTS
RADIOTHERAPY
TOXICITY